🧬 ICD-10 CM E21.1 — Secondary Hyperparathyroidism, Not Elsewhere Classified
Billable Code Confirmed
ICD-10 CM E21.1 is a complete, fully-specified five-character code requiring no further subdivision, making it valid for direct claim submission across Medicare, Medicaid, and commercial payers for FY2026.¹ It captures secondary hyperparathyroidism arising from a non-renal chronic disease process, distinguishing it from the renal-origin variant classified separately.
Non-Billable Parent Codes
E21 (Hyperparathyroidism and other disorders of parathyroid gland) is a non-billable category header requiring selection of a fourth-character child code before claim submission.² It cannot itself appear on any claim and exists only to organize the more specific billable codes beneath it.
Clinical Context
The critical clinical distinction driving code selection is etiology: E21.1 applies when secondary hyperparathyroidism is documented without renal origin specified or with a non-renal chronic disease driver, while N25.81 applies specifically when chronic kidney disease is the documented cause. Because CKD is overwhelmingly the most common driver of secondary hyperparathyroidism in clinical practice, providers frequently fail to specify etiology clearly, creating a recurring CDI query trigger.
Code Classification
ICD-10 CM E21.1 is a diagnosis code only; it carries no procedural component and must always be paired with the appropriate CPT/HCPCS procedure or evaluation and management code to support any billed service.
🔍 Code Description
Secondary hyperparathyroidism reflects a compensatory increase in parathyroid hormone (PTH) secretion driven by an underlying disease process rather than intrinsic gland pathology, distinguishing it fundamentally from primary hyperparathyroidism (E21.0), which results from autonomous adenoma or hyperplasia within the gland itself. In the E21.1 presentation, the parathyroid glands respond appropriately to a chronic metabolic disturbance such as vitamin D deficiency, malabsorption, or another non-renal chronic condition that produces hypocalcemia or phosphate imbalance, and the resulting sustained PTH elevation can, over time, lead to parathyroid gland hyperplasia even though the initiating defect lies outside the gland.
Clinically, the workup mirrors other hyperparathyroid presentations and typically includes serum calcium, phosphate, vitamin D, and intact PTH assays, often supplemented by bone density or renal function studies to characterize downstream skeletal or metabolic consequences. Because chronic kidney disease is by far the most frequent driver of secondary hyperparathyroidism, documentation that fails to explicitly rule in or rule out renal etiology forces the coder to default to E21.1 as the “not elsewhere classified” option rather than the more specific N25.81, making provider query for etiology one of the most consequential steps in accurate code assignment for this diagnosis.
🌳 Code Tree / Hierarchy
E21 Hyperparathyroidism and other disorders of parathyroid gland ❌ Non-billable
│
├── E21.0 Primary hyperparathyroidism ✅ Billable
├── E21.1 Secondary hyperparathyroidism, not elsewhere classified ◀ THIS CODE ✅ Billable
├── E21.2 Other hyperparathyroidism ✅ Billable
│
├── E21.3 Hyperparathyroidism, unspecified ✅ Billable
├── E21.4 Other specified disorders of parathyroid gland ✅ Billable
└── E21.5 Disorder of parathyroid gland, unspecified ✅ Billable
Renal vs. Non-Renal Etiology Specificity
Because chronic kidney disease accounts for the vast majority of secondary hyperparathyroidism cases, many payers and MS-DRG groupers treat N25.81 as the expected default; assigning E21.1 on a patient with documented CKD without a clear provider query trail can trigger audit scrutiny for potential upcoding or miscoding of etiology.
Tip
Always cross-reference the encounter’s renal function labs and CKD staging documentation before finalizing E21.1 — if any CKD diagnosis appears elsewhere in the chart without explicit dissociation from the parathyroid finding, a physician query for causal linkage is warranted.
✅ Includes
- Secondary hyperparathyroidism where the documentation does not specify renal origin as the etiology.
- Secondary hyperparathyroidism attributable to a non-renal chronic disease process, such as malabsorptive vitamin D deficiency or chronic hypocalcemia from another documented source.
❌ Excludes
Excludes 1
- ICD-10 CM N25.81 — Secondary hyperparathyroidism of renal origin: mutually exclusive with E21.1 because renal-origin secondary hyperparathyroidism is classified exclusively under the genitourinary chapter, not the endocrine chapter.
- E34.2- (non-billable, requires further specificity) — Ectopic hyperparathyroidism: reflects PTH-like hormone secretion from a non-parathyroid tumor source, a fundamentally different mechanism than gland-based compensatory hyperplasia.
- E83.81- (non-billable, requires further specificity) — Hungry bone syndrome: represents a post-parathyroidectomy hypocalcemic state from rapid bone remineralization, not ongoing hyperparathyroidism itself.
Danger
The most common Excludes 1 error is defaulting to E21.1 on a CKD patient purely out of habit or template carryover, when the documentation actually supports the renal-origin code N25.81; this is a frequent target of payer-side coding audits given how disproportionately common CKD-driven secondary hyperparathyroidism is in practice.
Excludes 2
- E83.52- (non-billable, requires further specificity) — Familial hypocalciuric hypercalcemia: a distinct genetic calcium-sensing receptor disorder that can coexist with a separately documented secondary hyperparathyroidism process, so both may be coded together when clinically supported.
📋 Clinical Overview
Etiology-Driven Code Selection
Distinguishing E21.1 from its renal-origin counterpart requires the coder to trace the documented causal chain rather than relying on the presence of any single lab value, since elevated PTH alone is nonspecific across all hyperparathyroidism subtypes.
| Feature | E21.1 | Related E21.0 | Related N25.81 |
|---|---|---|---|
| Etiology | Non-renal chronic disease or unspecified secondary cause | Autonomous parathyroid adenoma/hyperplasia | Chronic kidney disease specifically |
| Calcium profile | Typically hypocalcemic or normocalcemic | Typically hypercalcemic | Typically hypocalcemic with hyperphosphatemia |
| Chapter | Endocrine (Chapter 4) | Endocrine (Chapter 4) | Genitourinary (Chapter 14) |
Important
Manifestations & Symptom Burden
- Bone pain and increased fracture risk from chronic PTH-driven bone turnover.
- Muscle weakness and fatigue associated with sustained calcium-phosphate derangement.
- Vascular and soft-tissue calcification risk in prolonged, poorly controlled cases.
Tip
Manifestations themselves are not separately coded unless independently documented as a distinct diagnosis (e.g., a pathologic fracture), in which case sequencing follows standard etiology/manifestation conventions.
💰 HCC Risk Adjustment
| Model | HCC Mapping | RAF Contribution |
|---|---|---|
| CMS-HCC V28 (current) | Not mapped | 0 |
| CMS-HCC V24 (legacy) | HCC 23 — Other Significant Endocrine and Metabolic Disorders | ~0.230 |
| ESRD/PACE | HCC 23 | Applicable |
| RxHCC | HCC 43 — Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders | Applicable |
ICD-10 CM E21.1 carries no risk-adjustment weight under the current CMS-HCC V28 model used for Medicare Advantage risk scoring, a meaningful shift from the legacy V24 model where it mapped to HCC 23.¹ Coders working in HCC capture or annual wellness contexts should verify which model version their payer or MA plan is actively using, since a V24-era workflow could overstate the RAF impact of this diagnosis. It retains relevance under ESRD/PACE and RxHCC frameworks, so dialysis-adjacent and Part D risk workflows should not assume the code is entirely risk-adjustment-inert.
🏥 MS-DRG Assignment
| Scenario | DRG Assignment |
|---|---|
| Principal diagnosis | DRG 643-645 (MDC 10 — Endocrine Disorders, stratified by MCC/CC/none) |
| Secondary diagnosis on CKD admission | Functions as a CC within the applicable renal/MDC 11 DRG when appropriately linked |
When E21.1 is the principal diagnosis, it groups within MDC 10’s endocrine disorder triad, with MCC/CC status of any coexisting condition determining the specific DRG tier and reimbursement weight. Far more commonly it appears as a secondary diagnosis on a chronic kidney disease or dialysis-related admission, where it can qualify as a CC depending on the base DRG, making its presence or absence a factor coders should verify has not been missed on renal encounters.
- NCD/LCD note: No NCD governs the diagnosis code itself, but MAC-level LCDs for parathyroid hormone (PTH) laboratory testing — such as the Parathormone LCD maintained by regional MACs — list E21.1 among the covered diagnosis indications supporting medical necessity for serum intact PTH assays.³ Verify current diagnosis-to-CPT crosswalk coverage against your Noridian (JE/JF) LCD for PTH testing before submitting associated lab claims, since coverage criteria for screening versus diagnostic PTH testing differ.
🔗 Related ICD-10-CM Codes
Parathyroid disorder family: E21.0 (Primary hyperparathyroidism), E21.2 (Other hyperparathyroidism), E21.3 (Hyperparathyroidism, unspecified), E21.4 (Other specified disorders of parathyroid gland), E21.5 (Disorder of parathyroid gland, unspecified), N25.81 (Secondary hyperparathyroidism of renal origin).
Metabolic/renal context codes frequently co-reported: E83.52- (non-billable, requires further specificity — familial hypocalciuric hypercalcemia), E55.9- (non-billable, requires further specificity — vitamin D deficiency, unspecified), N18.- (non-billable, requires further specificity — chronic kidney disease staging), E83.81- (non-billable, requires further specificity — hungry bone syndrome).
🛠️ Commonly Associated CPT Codes
- 83970 (verify current status against live CMS Clinical Laboratory Fee Schedule — not present on the PFS) — Parathyroid hormone (PTH) assay, the primary diagnostic lab test confirming and monitoring secondary hyperparathyroidism.
- 82310 (verify current status against live CMS Clinical Laboratory Fee Schedule — not present on the PFS) — Calcium, total; commonly ordered alongside PTH to characterize the biochemical profile.
- 82330 (verify current status against live CMS Clinical Laboratory Fee Schedule — not present on the PFS) — Calcium, ionized; used when free calcium fraction assessment is clinically indicated.
- 60500 — Parathyroidectomy or exploration of parathyroid(s); billed when medical management fails and surgical intervention is pursued, carries a 090-day global period.⁴
- 60502 — Reexploration of parathyroid(s); applicable for persistent or recurrent hyperparathyroidism after initial surgery, also a 090-day global period.⁴
- 60505 — Parathyroidectomy or exploration of parathyroid gland(s) with mediastinal exploration, sternal split or transthoracic approach; reserved for complex or ectopic gland cases, 090-day global period.⁴
🏷️ Modifier Reference
| Modifier | Name | When to Apply |
|---|---|---|
| -59 | Distinct Service | Apply when a lab test or procedure billed alongside another parathyroid-related service must be distinguished as a separately identifiable, non-overlapping service. |
| -78 | Return to OR | Apply when reexploration (60502) is required during the global period of an initial parathyroidectomy for a related complication. |
| -79 | Unrelated Procedure | Apply when a subsequent parathyroid procedure occurs during the global period of an unrelated prior surgery performed by the same physician. |
| -52 | Reduced Services | Apply when a planned parathyroid exploration is intentionally reduced in scope relative to the standard procedure description. |
| -53 | Discontinued | Apply when a parathyroidectomy is discontinued after induction due to patient risk factors before the procedure is completed. |
NCCI Bundling Considerations
PTH assay and calcium testing are not typically bundled with each other under NCCI edits when both are separately medically necessary and clearly ordered, but repeat same-day PTH testing without documented clinical justification (e.g., intraoperative rapid PTH monitoring) can trigger frequency-based denial rather than a strict NCCI pair edit.
🔬 ICD-10-PCS Crosswalk
0GB03ZZ— Excision of Parathyroid Gland, Percutaneous Approach; used for a percutaneous biopsy or partial excision approach when imaging-guided sampling is performed rather than open exploration.0GB04ZZ— Excision of Parathyroid Gland, Percutaneous Endoscopic Approach; applicable when minimally invasive endoscopic technique is documented for gland excision.0GT00ZZ— Resection of Parathyroid Gland, Open Approach; the standard PCS code for a complete open parathyroidectomy corresponding to CPT 60500 or 60505.
💊 Coding Scenarios and Examples
Example 1
Clinical Scenario: A 68-year-old male with a history of malabsorptive bariatric surgery presents with fatigue and bone pain. Labs reveal low-normal calcium, low vitamin D, and elevated intact PTH. Renal function is documented as normal, and the provider attributes the hyperparathyroidism to chronic malabsorption rather than renal disease.
| Field | Code | Rationale |
|---|---|---|
| CPT | 83970 (verify current status against live CMS Clinical Laboratory Fee Schedule) | Confirms elevated intact PTH supporting the diagnosis. |
| PDx | E21.1 | Renal etiology explicitly excluded by normal renal function and documented malabsorptive cause, supporting the non-renal secondary code. |
Tip
The explicit exclusion of CKD in the documentation is what justifies E21.1 over N25.81 here — without that clear statement, a query for etiology would be required. CDI note: flag any chart where malabsorption and mild renal impairment coexist for etiology clarification, since dual contributing factors are common in this population.
Example 2
Clinical Scenario: A 55-year-old female is admitted for elective parathyroidectomy after failed medical management of hyperparathyroidism secondary to long-standing vitamin D deficiency unrelated to renal disease. The procedure proceeds without complication via standard cervical exploration.
| Field | Code | Rationale |
|---|---|---|
| CPT | 60500 | Standard parathyroidectomy/exploration performed via cervical approach. |
| PDx | E21.1 | Documented vitamin D deficiency as the driving etiology, with renal disease explicitly ruled out. |
Tip
Sequencing places E21.1 as principal since it is the reason for the admission and the surgical target. CDI note: verify vitamin D deficiency is separately documented and coded if it meets reportable criteria as an additional diagnosis.
Example 3
Clinical Scenario: A 72-year-old male with stage 3 CKD is admitted for an unrelated orthopedic procedure. During the stay, labs incidentally reveal elevated PTH, and the physician documents “secondary hyperparathyroidism, etiology unclear, will need outpatient workup” without linking it definitively to the known CKD.
| Field | Code | Rationale |
|---|---|---|
| CPT | 83970 (verify current status against live CMS Clinical Laboratory Fee Schedule) | Confirms the incidental PTH elevation. |
| PDx | E21.1 | Used only provisionally pending etiology clarification; a query should be initiated before final code assignment given the coexisting CKD. |
Tip
This scenario is a textbook CDI query trigger — coexisting CKD with unlinked secondary hyperparathyroidism should never be finalized as E21.1 without first attempting physician clarification toward N25.81. CDI note: document the query attempt and outcome in the record for audit-defense purposes regardless of which code is ultimately finalized.
⚠️ Coding Pitfalls and Tips
- Pitfall 1: Defaulting to E21.1 whenever a CKD patient has elevated PTH, without confirming the provider has not simply omitted the renal linkage; Tips: always cross-check the chart for CKD staging codes before finalizing this diagnosis and query when etiology is ambiguous.
- Pitfall 2: Coding both E21.1 and N25.81 together on the same encounter; Tips: remember these are Excludes 1 mutually exclusive codes and only one etiology designation should be assigned.
- Pitfall 3: Assuming this code carries HCC risk-adjustment weight under the current model; Tips: confirm which CMS-HCC model version (V24 vs. V28) applies to the payer before including it in RAF capture projections.
- Pitfall 4: Overlooking the CC impact this code can add to a CKD-related DRG when it appears only as a secondary diagnosis; Tips: review the full secondary diagnosis list on renal admissions to ensure it is not inadvertently dropped from abstraction.
- Pitfall 5: Billing PTH-related lab CPT codes without confirming the diagnosis is listed as a covered indication on the applicable MAC’s LCD; Tips: check the Noridian JE/JF Parathormone LCD coverage criteria before claim submission to avoid denial.
- Pitfall 6: Coding manifestations like bone pain or fatigue as separate diagnoses when they are integral, non-specific symptoms of the hyperparathyroidism itself; Tips: apply standard integral-symptom coding guidelines and only code manifestations separately when independently significant or unrelated.
📚 Sources
1. HCC Buddy. *E21.1 ICD-10-CM Code: Secondary Hyperparathyroidism, Not Elsewhere Classified — CMS-HCC V28/V24 Risk Model Data.* 2026. https://hccbuddy.com/icd10/E21.1 2. AutoICD API / ICD-10-CM Code Reference. *E21 — Hyperparathyroidism and Other Disorders of Parathyroid Gland.* Centers for Medicare and Medicaid Services and the National Center for Health Statistics; FY2026. 3. First Coast Service Options. *Local Coverage Determination (LCD) L34018 — Parathormone (Parathyroid Hormone).* Centers for Medicare and Medicaid Services Medicare Coverage Database. 4. CMS PPRRVU2026_Jan_QPP.xlsx. *Physician Fee Schedule Relative Value File, January 2026 (CPT 60500, 60502, 60505 — Status A, 090-day global).* Centers for Medicare and Medicaid Services; 2026.Sources listed above correspond to superscript citations throughout this note. Verify all Medicare payment figures against your current CMS PFS Lookup tool and applicable MAC LCD prior to claim submission. Please use the latest AAPC/AHIMA Coding Books to verify each code within this note.